{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=26",
    "query": {
      "condition": "Oral Cavity",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 6517,
    "total_pages": 652,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Oral+Cavity&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T04:09:28.466Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03017235",
      "title": "A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bowel Preparation"
      ],
      "interventions": [
        {
          "name": "Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 917,
      "start_date": "2017-02-20",
      "completion_date": "2017-10-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 12,
      "location_summary": "Huntsville, Alabama • Anaheim, California • Chula Vista, California + 9 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03017235"
    },
    {
      "nct_id": "NCT01263197",
      "title": "A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "LY2216684",
          "type": "DRUG"
        },
        {
          "name": "albuterol",
          "type": "DRUG"
        },
        {
          "name": "propranolol",
          "type": "DRUG"
        },
        {
          "name": "placebo for LY2216684",
          "type": "DRUG"
        },
        {
          "name": "placebo for albuterol",
          "type": "DRUG"
        },
        {
          "name": "placebo for propranolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2010-12",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01263197"
    },
    {
      "nct_id": "NCT02497235",
      "title": "A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "[18F]MNI-792 (tracer)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-07",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02497235"
    },
    {
      "nct_id": "NCT04216576",
      "title": "A Study of the Use of Text Message Reminders to Take Palbociclib",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paper Drug Diary",
          "type": "OTHER"
        },
        {
          "name": "OhMD APP",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2019-12-27",
      "completion_date": "2026-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04216576"
    },
    {
      "nct_id": "NCT05225389",
      "title": "Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "300 mg [C14] CT1812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cognition Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "19 Years to 55 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2021-12-31",
      "completion_date": "2022-01-24",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05225389"
    },
    {
      "nct_id": "NCT00425750",
      "title": "Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2005-08",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2011-11-16",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 7,
      "location_summary": "Hopkinsville, Kentucky • Paducah, Kentucky • Crossville, Tennessee + 3 more",
      "locations": [
        {
          "city": "Hopkinsville",
          "state": "Kentucky"
        },
        {
          "city": "Paducah",
          "state": "Kentucky"
        },
        {
          "city": "Crossville",
          "state": "Tennessee"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00425750"
    },
    {
      "nct_id": "NCT02649608",
      "title": "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "0.04 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.08 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.2 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.4 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.6 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.8 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "1.2 mg Lu AE04621",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 4,
      "location_summary": "Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649608"
    },
    {
      "nct_id": "NCT03626376",
      "title": "Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex Virus Keratitis"
      ],
      "interventions": [
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily",
          "type": "DRUG"
        },
        {
          "name": "oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2019-12-10",
      "completion_date": "2022-03-02",
      "has_results": false,
      "last_update_posted_date": "2022-01-14",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626376"
    },
    {
      "nct_id": "NCT03417076",
      "title": "Absolute Bioavailability Study With Bexagliflozin",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bexagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theracos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2018-08-01",
      "completion_date": "2018-09-16",
      "has_results": false,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417076"
    },
    {
      "nct_id": "NCT00502125",
      "title": "In Vivo Confocal Imaging of Oral Mucosa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Oral Tumors"
      ],
      "interventions": [
        {
          "name": "Reflectance Confocal Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2003-01",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2012-08-01",
      "last_synced_at": "2026-10-26T04:09:28.466Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00502125"
    }
  ]
}